CA
KNSA icon

Cornerstone Advisory’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cornerstone Advisory’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$2K – 505
2021
Q4 		$2K Buy
+200
New +$2.46K ﹤0.01% 730

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cornerstone Advisory's KNSA Position: Q1 2022 in Review

Cornerstone Advisory sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2022, closing a stake of 200 shares — an estimated $2K sold.

Cornerstone Advisory first reported a position in KNSA in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 96 funds tracked by Wall St. Rank hold KNSA as of Q1 2022.

  • Cornerstone Advisory reported no remaining Kiniksa Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cornerstone Advisory sold 200 Kiniksa Pharmaceuticals shares in Q1 2022, an estimated $2K.
  • Cornerstone Advisory first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Cornerstone Advisory's Kiniksa Pharmaceuticals position peaked at $2K in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.